From Wikipedia - Reading time: 3 min
| Discipline | Toxicology and pharmacology |
|---|---|
| Language | English |
| Edited by |
|
| Publication details | |
| History | 1981–present |
| Publisher | Elsevier on behalf of the International Society of Toxicology & Pharmacology |
| Frequency | Monthly |
| 3.271 (2021) | |
| Standard abbreviations | |
| ISO 4 | Regul. Toxicol. Pharmacol. |
| Indexing | |
| CODEN | RTOPDW |
| ISSN | 0273-2300 |
| LCCN | 81646304 |
| OCLC no. | 485750423 |
| Links | |
Regulatory Toxicology and Pharmacology is a monthly peer-reviewed scientific journal which covers legal aspects of toxicological and pharmacological regulations. It is published by Elsevier on behalf of the International Society of Regulatory Toxicology & Pharmacology. The current co-editors-in-chief are Lesa L. Aylward and Martin van den Berg.
In 2002, a group of 45 academics wrote a letter accusing the journal of a concealed pro-industry bias, a possible lack of full and independent peer review, and a failure to disclose conflicts of interest, citing a case in which Gio Batta Gori, then-current editor-in-chief, was paid $30,000 by the Tobacco Institute to write an article later published in the journal dismissing the health risks of secondhand smoke.[1][2] The letter's coordinator later commented that the journal "reads like an industry trade publication, but it's masked as a peer-reviewed journal" and that it lacked any "credible peer-review process."[3] In response, the journal's publisher implemented a conflict of interest disclosure policy at the journal in January 2003, shortly before the correspondence was published.[1]
The journal is abstracted and indexed in EMBASE, EMBiology, and Scopus.
According to the Journal Citation Reports, the journal has a 2014 impact factor of 2.031, ranking it 56th out of 87 journals in the category "Toxicology"[4] and 146th out of 254 journals in the category "Pharmacology & pharmacy".[5]